In vitro and in vivo data provide compelling evidence for an interaction between the RAS and thrombosis. Furthermore, angiotensin and AT 1 receptor blockers may influence platelet function. ACE is strategically poised to regulate these interactions. ACE catalyzes the conversion of Ang I to Ang II, which in turn stimulates the production of PAI-I, sensitizes platelets, promotes the production of superoxide radicals that scavenge free NO, and induces the expression of tissue factor. Conversely, ACE catalyzes the breakdown of bradykinin, a potent stimulus to t-PA secretion. These data suggest that clinical, genetic, or environmental factors (such as salt intake and medications) that alter ACE activity and Ang II production would be expected to impact on clotting and fibrinolytic mechanisms.
|Original language||English (US)|
|Number of pages||11|
|Journal||Advances in Internal Medicine|
|State||Published - Dec 1 2000|
ASJC Scopus subject areas
- Internal Medicine